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Abstract  
Introduction: Research suggests that people with schizophrenia have autonomic dysfunctions. 
These have been linked to functioning problems, symptoms and considered a risk factor for 
illness chronicity. The aim of this study is to introduce a new Mobile Health (mHealth) 
method using wearable technology to assessing autonomic activity in people’s everyday life. 
We aim to evaluate the new method acceptability and characterise the association between 
schizophrenia illness features and autonomic abnormalities. 
Method: Thirty participants with schizophrenia and 25 controls were asked to wear a mHealth 
device measuring autonomic activity and movements during their normal everyday life. 
Measures of device use acceptability were collected from all participants. Participants with 
schizophrenia were also assessed for symptoms and functioning levels. Measures of heart rate 
variability (HRV), electrodermal activity (EDA) and movement were collected by the device 
and groups were compared. Correlation between physiological measures, functioning, 
symptoms and medication levels were assessed in people with schizophrenia.  
Results: The mHealth device method proved to be acceptable and produced reliable measures 
of autonomic activity and behaviour. Compared to controls, people with schizophrenia 
showed lower levels of HRV, movement and functioning. In people with schizophrenia 
illness severity, particularly positive symptoms, was associated with parasympathetic 
deregulation. 
Conclusions: Autonomic abnormalities can be detected using wearable technology from 
people’s everyday life. These are in line with previous research and support the notion that 
autonomic deregulation are relevant illness features for mental and physical health in 
schizophrenia. This method may be developed as a monitoring system well-being and relapse 
prevention. 
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Introduction  
People with schizophrenia experience a significant reduction in their functioning 
levels from illness onset (Cella et al., 2016; Reichenberg et al., 2014). Functioning problems 
are largely responsible for the long term consequences of the illness, poor life quality and 
much of the illness associated burden for sufferers, carers, the health care system and the 
society (Harvey, 2009; Jaaskelainen et al., 2013; Stouten et al., 2014). Much of the work 
done in this area has used interview based tools to assess the illness impact on social and 
occupational levels (Cella et al., 2016; Heinrichs et al., 2006; Schneider and Struening, 
1983). 
Challenges in the definition of functioning and its broad conceptualisation have made 
it difficult to study the biological markers associated with this illness feature. One exception 
is research in the field of autonomic nervous system activity. Since the ‘80s autonomic 
system dysfunction have been consistently linked to functioning difficulties in people with 
schizophrenia (Brekke et al., 1997; Ohman et al., 1989; Tarrier and Barrowclough, 1990). 
Despite not always converging in identifying a specific biological system, the majority of the 
evidence supports the notion that autonomic deregulation may be implicated in functioning 
problems (Fujibayashi et al., 2009). Several studies suggest that reduce vagal tone and heart 
rate variability (HRV) are found in people with schizophrenia, and to a lesser degree in 
unaffected relatives (e.g. Bar et al., 2005; Ieda et al., 2014; Moon et al., 2013) and this is 
associated with lower scores on the Global Assessment of Functioning (Khandoker et al., 
2010), illness chronicity (Toichi et al., 1999) and both positive and negative symptoms 
severity (Boettger et al., 2006; Kim et al., 2004b). A recent meta-analysis suggested that this 
feature should be considered an endophenotype of schizophrenia (Clamor et al., 2016). Less 
convergent are findings from studies investigating sympathetic regulation. Some studies 
found people with schizophrenia displaying elevated event related phasic and tonic 
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electrodermal activity, EDA, compared to controls (Zahn et al., 1997) while other studies 
found no differences (Castro et al., 2008; Hempel et al., 2005). Recently Motaquila et al., 
(Montaquila et al., 2015) proposed that sympathetic deregulation in people with 
schizophrenia may be dependent on diminished parasympathetic activity and the consequent 
difficulties of the parasympathetic system to down-regulate sympathetic activity. This 
account may explain the incongruent sympathetic activation findings and explain why event-
related activation is largely found in the normal range while there may be a selective 
difficulty in down-modulating this response. To date only a limited number of studies 
measured sympathetic and parasympathetic activity simultaneously and therefore this 
hypothesis has only partial empirical support.  
Most of the studies available in the literature assess the relationship between 
autonomic activity and schizophrenia illness features using laboratory based paradigms. This 
method however does not allow assessing directly the relevance of autonomic events to 
functioning problems. Recent technological developments produced devices capable of 
recording autonomic activity from wearable devices. These are worn on such as regular 
cloths or watches and allow regular information gathering over extended time periods. This 
new prospect has made physiological research outside the laboratory accessible and  allowed, 
for the first time, to study how autonomic deregulations contribute to mental health 
symptoms (Okruszek et al., 2016). This methodology is also beginning to be used for 
monitoring and prevention in neurological and cardiometabolic conditions (Corino et al., 
2017; Picard et al., 2017; Sarkis et al., 2015) 
The use of wearables and mobile health (mHealth) devices in people with 
schizophrenia may also be useful to support intervention to improve cardiometabolic health 
(Mitchell and De Hert, 2015). Resent research suggested that wearable devices may be useful 
6 
 
to support weight loss and improve lifestyle in people with severe mental health condition 
(Naslund et al., 2016; Naslund et al., 2017) . 
This study has three aims. The first is to evaluate the acceptability and feasibility of 
the new mHealth technology in people with schizophrenia. The second is to compare 
sympathetic and parasympathetic activity between people with schizophrenia and healthy 
controls during everyday life. The third is to assess the association of possible autonomic 
abnormalities with functional difficulties and symptoms of schizophrenia.  
 
Methods 
Design 
Cross-sectional comparing a group of people with schizophrenia with a control group.  
Participants 
Participants with schizophrenia were recruited from the National Health System, 
Community Mental Health Teams in South London (UK). Inclusion criteria were: (i) DSM-
IV diagnosis of schizophrenia, (ii) aged 18–65, (iii) good command of English language. 
Exclusion criteria: (i) recent medication change (i.e. in the last month), (ii) poor literacy or 
learning disability, (iii) a DSM-IV diagnosis of substance dependence. Participants in the 
control group were healthy individuals recruited with advertisement from the local 
community to match the clinical group for age and gender. Inclusion criteria were set to allow 
appropriate group matching: age between 18–65 years, no history of DSM-IV diagnosis of 
schizophrenia or other mental disorder, no evidence of head injury/organic brain disorder, no 
learning disability and no diagnosis of substance dependence. 
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Measures 
For all participants we collected demographic information (e.g. age, gender). For 
participants in the clinical group we collected information on their mental health history and 
current medication. Antipsychotic dosage was converted to chlorpromazine equivalents using 
guidelines form Woods (Woods, 2003). 
 
Acceptability 
The assessment acceptability was evaluated using an acceptability feedback 
questionnaire. The assessment questions were designed to be rated using a 7-point Likert 
scale. Questions enquired whether: i) the device disrupted participants’ life; ii) stopped 
participants from doing usual activities; iii) it was embarrassing to wear the device around 
other people; iv) it was easy to remember to wear the device; v) it was enjoyable wearing the 
device as part of this study. This measure was used in a previous study involving people with 
schizophrenia and a similar mHealth device (Edwards et al., 2016).   
 
Functioning  
Functioning was assessed with the time use survey (Short, 2006). This is a semi-
structured interview asking participants to retrospectively report the time spent in a variety of 
activities in the last month (e.g. work, education, socializing, sleep). Time spent in each 
activity is converted in number of hours per week. Time spent in structured activity is 
considered and index of function levels. Structured time includes activities such as work, 
volunteering, studying, socializing, travelling, hobbies, house chores, caring for others and 
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looking after children. This measure was used in previous research with people with 
schizophrenia (Cella et al., 2016).  
Symptoms  
Symptom severity was measured using the Positive and Negative Syndrome Scale 
(PANSS) (Kay et al., 1987). This is a 30-item assessing symptom severity in the past week. 
For this study we considered five factors: Positive Symptoms (Pos), Negative Symptoms 
(Neg), Disorganised (Dis), Excited (Exc) and Negative Emotion Depressed (Emd) (Cella et 
al., 2014a; Wallwork et al., 2012).  
 
Autonomic system  
The measurement of the autonomic activation was conducted using a mHealth 
wearable device worn on the participant’s wrist (i.e. Empatica E4) (Garbarino et al., 2014). 
The device has 3 sensors recording: i) Electrodermal Activity (EDA) via skin conductivity. 
This assesses overall responsiveness to external events by assessing sympathetic nervous 
system arousal; ii) Blood volume pulse with a photoplethysmography sensor. From this 
measure it is possible to extract time between heart beat peaks (inter-beat intervals IBI). From 
IBI data it is possible to extract hear rate variability (HRV); inter-beat intervals (RR); 
standard deviation of RR intervals (SDNN) and square root of the mean squared differences 
of successive RR intervals (RMSSD); iii) Acceleration (ACC) via a 3-axis accelerometer. 
Data from this sensor can be used to calculate overall activity levels. 
 
Procedure 
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For the clinical group eligible participants who were considered suitable by their care 
team were approached and offered to take part in the study. Upon entering the study 
demographic and clinical information were collected from clinical records and during the 
initial assessment appointment all the study assessment measures were administered. 
Participates in the control group were screened for current and past mental health problems 
using the Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998). All 
participants were briefed on the use of the mHealth device and asked to wear it as much as 
possible for the following 6 days for the moment they wake up in the morning until bed time 
in the evening. Participants were asked to remove the mHealth device in case this could get in 
touch with water (e.g. showering, swimming). Participants were contacted by phone twice 
during the assessment period by a study researcher for troubleshooting. Information collected 
by the wearable device was stored on the device memory and downloaded on the study server 
during a research visit. After the sixth day participants met again with the researcher, returned 
the device and completed the acceptability measures.  
 
Data pre-processing 
Participants returned recording segments of different length. We initially decided to 
exclude short recordings (i.e. less than 60 minutes) as some HRV parameters (e.g. SDNN) 
may be less informative over a shorter recording period. Further we opted to consider only 
longer recordings as these were considered more likely to include a different range of 
activities. After preliminary inspection we noticed that all participants had several continuous 
recording exceeding 8 hours. We therefore decided to use only samples that had at least this 
length. All participants had at least two 8-hour samples. During the six days in which they 
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were asked to wear the device participants with schizophrenia completed on average 3.7 
(SD1.3) 8-hour samples while controls 3.8 (SD1.2).  
The EDA sensor collected data at a frequency of 4Hz while the ACC sensor sampled 
at 32 Hz. The IBI sensor returned the time between heartbeat peaks. EDA data was handled 
using Ledalab for MATLAB to remove artefacts  (Benedek and Kaernbach, 2010). Mean 
EDA amplitude was calculated for each sample. Heart rate variability parameters were 
calculated using IBI values  from the Empatica Algorithm 1 and 2 (see Garbarino et al., 
2014). Data was further processed with Kubios HRV (Tarvainen et al., 2014) to extract 
standard deviation of all normal RR intervals (SDNN) and root mean square of the successive 
differences of RR intervals (RMSSD) (Sollers et al., 2007).  
From the ACC sensor we extracted an index of overall movement by means of 
standard Euclidean metric. This was computed for each of the 3-axis sensor at each sampling 
point and summed for the total recording sample length, thus producing an indicator of 
overall extent of movement during the recording period.   
 
Data analysis 
Data analysis was divided into three stages. Firstly the relationship between 
physiological variables was examined with Spearman rho correlation coefficient to assess the 
reliability of the parameter extracted. Secondly, we examined between group differences with 
a set of t-tests and univariate ANOVAs. Before this analysis we assessed distribution 
normality using the Shapiro–Wilk test. We follow-up any significant findings with a post-hoc 
analysis controlling for age, time spent in structured activities (from the time-use survey) and 
activity levels (as recorded by the accelerometer sensor). Finally, we assessed the relationship 
between the clinical and functional measures and physiological variables using Spearman 
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rank correlations. For this analysis we controlled for multiple correlation and adjusted the 
significance threshold to a more conservative p=0.008 (Benjamini and Hochberg, 1995). For 
all other analysis the significant threshold was set at p<0.05.  
 
Results 
Table 1 shows the demographic characteristics for the two groups and the clinical 
characteristics for people with schizophrenia. The only significant difference was in the 
amount of time spent in structured activities.   
 
--- Table 1 about here --- 
 
 
Acceptability  
All participants were able to use the watch according to the instructions received and 
completed the device acceptability questionnaire. The result showed very similar 
acceptability scores between the two groups. When asked about the acceptability of the 
research procedures and the mHealth device use, people with schizophrenia endorsed at least 
a good or excellent rating 81% of the times across all the items while controls endorsed the 
same ratings 80% of the times.  
  
Physiological data validity  
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We calculated correlations between the physiological variables to assess validity. As 
expected HRV parameters showed strong and significant inter-correlations: mean RR 
correlated with SDNN (rho=0.55; p<0.001) and with RMSSD (rho=0.47; p<0.001), SDNN 
was correlated with RMSSD (rho=0.77; p<0.001). Also total movement levels were 
positively correlated with EDA (rho=0.47; p=0.002) and RR RMSSD (rho=0.29; p=0.037). 
 
Group differences   
Kolmogorov-Smirnov test revealed that EDA and ACC values were non-normally 
distributed. For these variables we repeated the analyses using non-parametric tests.  There 
were no group differenced in EDA (Mann-Whitney U=126.0, n.s., see Figure 1). Significant 
differences were found for SDNN (F(1,52)=6.4, p=0.015; SCZ: 102+/-34 vs. HC:129+/-44) 
and RMSSD (F(1,52)=7.7, p=0.008; SCZ: 70+/-25 vs. HC: 90+/=27) and a trend toward 
significance for mean RR, F(1,52)=4.5, p=0.07; SCZ: 771+/-121 vs. HC: 839+/-147 (see 
Figure 1). In all these measures, participants with schizophrenia had lower values. Group 
comparison on ACC data showed that people with schizophrenia had overall lower  
movement levels than controls, F(1,52)=5.3 p=0.02). As ACC data were skewed we 
replicated this result using non-parametric statistics (Mann-Whitney U=470.5 p=0.03). 
Participants in the controls group had more hours of structured activity compared with 
people with schizophrenia, F(1,52)=74.4, p<0.001; SCZ: 36+/-21 vs. HC: 108+/-39. This 
result was confirmed with non-parametric testing (Mann-Whitney U=684, p<0.001). We 
repeated all the analysis on physiological measures controlling for age, time-use structured 
activity and movement. The only significant difference still observed was in RR RMSSD, 
F(1,49)=4,6; p=0.04. 
--- Figure 1 about here --- 
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Correlations with clinical/functional measures 
In people with schizophrenia RR SDNN negatively correlated with Positive 
symptoms (rho=-0.50, p=0.007) while movement negatively correlated with Negative 
symptoms (rho=-0.51, p=0.006). Number of weekly hours of structures activity correlated 
with movement levels (rho=0.43, p=0.02) and negatively with mean RR (rho=-0.50, 
p=0.007). We did not find association between medication and any of the autonomic 
parameters measured.  
 
Discussion 
In this study we evaluated the acceptability and feasibility of a new mHealth method 
assessing autonomic activity in everyday life in people with schizophrenia. We also 
compared measures of sympathetic and parasympathetic activity collected with this method 
from people’s everyday life between people with schizophrenia and healthy controls. Finally 
we assessed the association between autonomic abnormalities, functional difficulties and 
symptoms of schizophrenia.  
Our data on acceptability and feasibility suggest that this is a viable methodology for 
clinical studies. Evaluating these parameters is a necessary and important first step when 
testing new methodologies. mHealth devices present clinicians and researchers with an 
unprecedented opportunity to assess physiological parameters in real time and without 
interfering with people’s lives. This may be particularly important for studies aiming to 
understand barriers to recovery in people with psychosis as autonomic deregulation has been 
found to be associated with different illness chronicity features (e.g. Bar et al., 2008; Chung 
et al., 2013; Kim et al., 2004b; Valkonen-Korhonen et al., 2003).  
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In line with previous research our findings shows that people with schizophrenia have 
autonomic abnormalities, in particular reduced HRV (Bar et al., 2007; Iwamoto et al., 2012; 
Kim et al., 2004b). Previous research suggests that HRV reduction may be associated with 
reduced functioning (Fujibayashi et al., 2009; Valkonen-Korhonen et al., 2003). A number of 
hypotheses have been advanced on the role of autonomic deregulations and functioning in 
people with schizophrenia. Our findings suggest, in line with Montaquila et al., that 
autonomic abnormalities are mostly relevant for the parasympathetic branch of the autonomic 
system (Montaquila et al., 2015). This suggests that people with schizophrenia may have 
adequate reactivity to arousing stimuli but the parasympathetic system may fail to down-
regulate this activation following habituation or stimulus removal. This study did not find 
abnormal EDA values in the clinical group and this may be dependent on the length of the 
recording period used (i.e. 8 hours). Most of the studies showing abnormal sympathetic 
activity in people with schizophrenia use experimental designs evaluating event related 
activation on a much shorter timescale (e.g. Castro et al., 2008).  
Lower parasympathetic activity in the group of people with schizophrenia was 
particularly evident for the standard deviation of RR intervals after controlling for age, 
functioning and movements levels. This index is considered more adequate for longer 
recordings as it measures HRV cycles over prolonged time periods and is relatively 
independent from activity levels therefore suggesting that HRV abnormalities may be related 
to other illness features such as symptoms (Thayer et al., 2012). This result did not entirely 
support the hypotheses that parasympathetic abnormalities are linked to functioning 
difficulties (Khandoker et al., 2010; Tarrier and Barrowclough, 1990; Toichi et al., 1999). 
However, it may be possible to reconcile these positions by considering how fundamental to 
schizophrenia both parasympathetic deregulation and functioning problems are. It is likely 
that relevant moderating and mediating factors may intervene in modulating this relationship 
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and perhaps contribute more decisively to explain this relationship. Our correlational analysis 
offers a potential candidate mediator for future study: positive symptoms. Previous studies 
have also fund this symptom cluster to be associated with autonomic deregulation and 
functioning problems (Kim et al., 2004a). It is also possible that poor functioning may be 
more influenced by other psychosocial aspects associated with psychoses such as limited 
opportunities and social contact, poor of self-esteem, social anxiety and low mood (Achim et 
al., 2011; Cella et al., 2014b; Saarni et al., 2010). The causal pathway to reduced HRV in 
psychosis remains uncertain and is unclear HRV is the cause or the consequence of reduced 
functioning.  
This study has limitations. We did not exclude participants on the basis of their 
medication intake. It has been suggested in the literature that some drugs (e.g. anticholinergic 
medications) may have an effect on the parasympathetic systems (Agelink et al., 2001; Kim 
et al., 2013; Rechlin et al., 1994). However these studies have not been replicated and poorly 
adapt to the reality of clinical services where polypharmacy is common. We recorded 
chlorpromazine equivalent levels and controlled for it in the analysis; however we did not 
find medication having a significant influence on any of the physiological parameters 
recorded. A recent meta-analysis by Alvares et al., (Alvares et al., 2016) supports our finding 
and suggests that the impact of antipsychotic medication on HRV in people with 
schizophrenia is small and largely non-significant. Two of our participants in the clinical 
group were also prescribed with an antidepressant medication. Future studies should consider 
more systematically the role of depression and antidepressants as this may influence HRV 
(Brunoni et al., 2013). Aside of medication tobacco use should also be considered in future 
investigations as this may have an effect on the autonomic system. We did not record 
people’s activity levels using self-assessed method (e.g. diary) as we wanted to record 
autonomic function without interfering with people’s everyday life. As a result many 
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participants reported that they were “forgetting” they were wearing a device. This is a 
positive aspect when considering future possible routine use of wearable devices however 
this meant that we were not able to monitor precisely people’s activities. In the future studies 
should consider using, alongside wearable devices, Experience Sampling Methodology 
(ESM) (Nelson et al., 2017). This method has now been used extensively in people with 
psychosis (Edwards et al., 2016). Using ESM in combination with mobile autonomic 
monitoring will link more clearly how changes in mental health states affect people’s 
autonomic system and give us the opportunity to devise precise and truly personalized 
monitoring systems.  
The more routine use of mHealth device in people with psychosis may have important 
benefits. Several reports suggest that physical health is poor in people with psychosis (Stubbs 
et al., 2016; Vancampfort et al., 2015). Routine assessment of behavioral and physiological 
parameters such as activity levels and HRV could provide key information on people’s 
wellbeing. Future interventions should capitalize on the possibility of tracking physiological 
parameters and monitoring changes regularly.  
 
 
Table 1 
 
 SCZ  M [SD] HC M [SD] Χ2 or t 
Gender 18 M / 10 F 13 M / 12 F Χ2=0.8 n.s. 
Age (years) 37.5 [10.8] 35.9 [12.5] t=0.5 n.s. 
Illness Lenght  11.8 [4.1]   
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(Yrs) 
PANSS5 Pos 9.8 [3.8] -  
PANSS5 Neg 12.7 [5.8] -  
PANSS5 Dis 7.7 [1.8] -  
PANSS5 Exc 6.0 [2.6] -  
PANSS5 Dep 9.9 [3.5] -  
CPZ (mg) 367 [337] -  
Structured 
Activity (hrs) 
36 [21] 108 [39] t=8.6*** 
*p<0.05; **p<0.01; ***p<0.001 
Table 1. Shows the mean (SD) of the demographic and clinical characteristics of people with 
schizophrenia (SCZ) and healthy controls (HC) 
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